Literature DB >> 17126660

Determinants for clinical diagnosis of hypertrophic cardiomyopathy.

A Selcuk Adabag1, Michael A Kuskowski, Barry J Maron.   

Abstract

Although hypertrophic cardiomyopathy (HC) occurs in 1 of 500 adults, most cardiology practices treat relatively few patients with HC, suggesting that many affected patients evade clinical recognition. Determining the clinical circumstances under which HC is identified will provide clues to its under-recognition. Clinical triggers leading to diagnostic echocardiograms were analyzed in 711 consecutive patients with HC. In most (384 [54%]), HC was initially suspected only after the onset of cardiac symptoms or acute cardiac events. In a substantial minority (327 [46%]), HC was recognized while patients were asymptomatic, including 225 (32%) by routine medical evaluations, in 27 of whom (4%) HC was recognized during preparticipation examinations for competitive sports or other activities. Women, older patients (age > or =50 years), and those with outflow obstruction at rest (gradient > or =30 mm Hg) were more likely suspected to have HC by virtue of cardiac symptoms or events (p <0.0001). Conversely, patients with extreme hypertrophy (wall thickness > or =30 mm) and those at high risk for sudden death were more often asymptomatic and identified by routine or family screenings (p <0.0001 and p = 0.004, respectively). Patients who subsequently died of heart failure or experienced embolic stroke were more often identified by virtue of symptoms or acute events (p = 0.03). In conclusion, although most patients with HC were recognized clinically only after overt disease manifestations, a substantial minority were diagnosed by routine examinations while asymptomatic, including an important subset of patients with HC recognized solely because of findings on sports preparticipation screening. These data underscore the need for heightened awareness and clinical suspicion of HC to increase the number of diagnosed patients, including many who may be at high risk for sudden death.

Entities:  

Mesh:

Year:  2006        PMID: 17126660     DOI: 10.1016/j.amjcard.2006.07.029

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  3 in total

Review 1.  Ethics of preparticipation cardiovascular screening for athletes.

Authors:  Barry J Maron; Richard A Friedman; Arthur Caplan
Journal:  Nat Rev Cardiol       Date:  2015-02-24       Impact factor: 32.419

Review 2.  Looking for hypertrophic cardiomyopathy in the community: why is it important?

Authors:  Stefano Nistri; Iacopo Olivotto; Francesca Girolami; Francesca Torricelli; Franco Cecchi; Magdi H Yacoub
Journal:  J Cardiovasc Transl Res       Date:  2009-10-20       Impact factor: 4.132

3.  Trends of the prevalence and incidence of hypertrophic cardiomyopathy in Korea: A nationwide population-based cohort study.

Authors:  Inki Moon; Seo-Young Lee; Hyung-Kwan Kim; Kyung-Do Han; Soongu Kwak; Minkwan Kim; Hyun-Jung Lee; In-Chang Hwang; Heesun Lee; Jun-Bean Park; Yeonyee E Yoon; Yong-Jin Kim; Goo-Yeong Cho
Journal:  PLoS One       Date:  2020-01-13       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.